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In studies of transgenic (Tg) mice that overexpress insulin-like
growth factor-I (IGF-I) exclusively in the CNS, we demonstrated
a dramatic increase in cerebellar granule cell number that ap-
peared to be attributable predominantly to enhanced survival.
IGF-I anti-apoptotic actions are well established in cultured
neurons, but comparable studies in vivo are few. Using the
same Tg mice, therefore, we set out to document IGF-I anti-
apoptotic effects during cerebellar development and to probe
IGF-I signaling mechanisms. Compared with cerebella (CBs) of
non-Tg littermates, those of Tg mice had fewer apoptotic cells
at postnatal day 7 (P7) and showed a similar tendency at P14
and P21. At each age studied, procaspase-3 and caspase-3
were decreased in CBs of Tg mice. The caspase-3 decline was
accompanied by decreases in the 85 kDa fragment of
Poly(ADP-ribose) polymerase, a known product of caspase
cleavage, suggesting decreased caspase activity. At P7 de-
creased apoptosis in Tg mice was associated with increased
expression of the anti-apoptotic Bcl genes, Bcl-xL and Bcl-2.
The mRNA expression of the proapoptotic Bcl genes, Bax and
Bad, also was increased, but no changes were observed in the
abundance of their proteins. At P14 Bcl-xL and Bcl-2 expres-
sion were similar in normal and Tg mice; Bax mRNA was
unchanged in Tg mice, but its protein abundance was de-
creased, and both Bad mRNA and protein abundance were
decreased. At P21 Bcl-xL and Bcl-2 expression were un-
changed, but Bax and Bad expression were decreased. Our
data show that IGF-I exerts anti-apoptotic actions during cer-
ebellar development, and thereby alters the magnitude of nat-
urally occurring apoptosis. IGF-I appears to affect multiple
steps in the apoptotic pathway in a developmentally specific
manner. IGF-I decreases caspase-3 availability and activity,
increases the expression of anti-apoptotic Bcl-xL and Bcl-2
during early postnatal development, and decreases proapop-
totic Bax and Bad expression at later developmental stages.
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Insulin-like growth factor-I (IGF-I) plays a significant role in the
stimulation of brain development (D’Ercole et al., 1996). IGF-I
overexpression in the brains of transgenic (Tg) mice results in
brain overgrowth (Carson et al., 1993; Ye et al., 1995, 1996) that
is characterized by an increase in neuron and oligodendrocyte
number and a marked increase in myelination. The increase in
cell number in IGF-I Tg mice appears to be attributable to both
stimulation of proliferation and an inhibition of apoptosis. Mice
with targeted disruptions of both IGF-I alleles have small brains
with decreased myelination and a reduction or absence in certain
neuron populations (Baker et al., 1993; Liu et al., 1993), and mice
that lack expression of the type I IGF receptor have a similar
phenotype (Baker et al., 1993; Liu et al., 1993). Many studies of
cultured cells (Matthews and Feldman, 1996; Baserga et al.,
1997), including those of cultured neurons and oligodendrocytes
(Baker et al., 1999; Ye and D’Ercole, 1999), demonstrate that
IGF-I is capable of promoting cell survival. Investigations into
whether IGF-I acts in vivo to inhibit apoptosis, however, are few.
In studies of one of our lines of IGF-I Tg mice, we obtained
evidence indicating that IGF-I stimulates cerebellar overgrowth
primarily by inhibiting apoptosis (Ye et al., 1996). These mice
carry a fusion gene that uses the mouse 59 genomic regulatory
region of the IGF-II gene to drive a human IGF-I cDNA (IGF-
II/IGF-I Tg mice). This transgene is expressed throughout the
brain beginning about the time of birth and exhibits highest
expression in cerebellum (CB). Compared with normal litter-
mates, the brains of heterozygous IGF-II/IGF-I Tg mice exhibit
overgrowth from the second week of postnatal life with the CB
exhibiting the greatest increase in size, such that by postnatal day
50 (P50) cerebellar weight is increased by 90%. The increased
weight is attributable to an increase in the total number of
granule and Purkinje cells (82 and 20% increases, respectively).
Granule cell proliferation is modestly increased only at P15,
making it unlikely that it is sufficient to account for the nearly
twofold increase in granule cell number. Increased cell survival,
therefore, appears to account for the increased cerebellar granule
cell number. Several other studies of intact mice provide evidence
consistent with IGF-I anti-apoptotic actions on neurons: (1)
IGF-I gene expression is low in the Purkinje cell degeneration
(pcd) mice, a mutant mouse line characterized by increased
cerebellar apoptosis (Zhang et al., 1997), and (2) IGF-I treatment
before experimental cerebral ischemia attenuates apoptosis in
hippocampal neurons (Tagami et al., 1997).
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The mechanisms by which IGF-I prevents cultured cells from
entering a death program have not been defined, and both the
phosphatidylinositol 39-kinase (PI3-K) and the mitogen-activated
protein kinase (MAP-K) pathways (Kulik et al., 1997; Parrizas et
al., 1997) have been implicated. Furthermore, a number of in vitro
studies link IGF-I actions to the Bcl family of proteins, but these
findings are somewhat discrepant. For example, IGF-I inhibition
of apoptosis is associated with: (1) increased Bcl-xL expression and
action (Singleton et al., 1996; Parrizas and LeRoith, 1997); (2)
increased Bcl-2 expression (Minshall et al., 1997); (3) suppressed
interleukin-1b-converting enzyme (caspase)-mediated cell death,
apparently through a mechanism independent of the expression of
Bcl-2, Bcl-xL, and Bax (Jung et al., 1996), and (4) an inactivation of
Bad by phosphorylation (del Peso et al., 1997; Dudek et al., 1997).
It seems likely that IGF-I anti-apoptotic actions differ among cell
types, at least when studied in culture. Studies of IGF-I anti-
apoptotic effects in vivo are essential, therefore, to clarify the
mechanisms by which IGF-I influences apoptosis.
Apoptosis leads to a massive loss of granule cells during active
neurogenesis in the first three postnatal weeks of cerebellar
development (Landis and Sidman, 1978; Wood et al., 1993).
Because IGF-I overexpression in IGF-II/IGF-I Tg mice occurs
when cerebellar apoptosis is active, study of these Tg mice is
especially useful to probe IGF-I anti-apoptotic effects. We hy-
pothesized that cerebellar overgrowth in these Tg mice is attrib-
utable, at least in large part, to IGF-I inhibition of granule cell
apoptosis and that these IGF-I actions are regulated by alter-
ations in the expression of genes for the Bcl family of proteins.
MATERIALS AND METHODS
Reagents. PCR reagents, DNA polymerase, digoxigenin and biotin-
labeled nucleotides, digoxigenin chemiluminescent detection reagents,
and positively charged nylon membranes were purchased from Roche
Molecular Biochemicals (Indianapolis, IN). Reverse transcriptase, RNA
polymerase and restriction enzymes were purchased from Promega
(Madison, WI), and a purification system for PCR products was pur-
chased from Qiagen (Chatsworth, CA). Reagents for RNase protection
assay (RPA) and detection system were obtained from Ambion (Austin,
TX). Trizol for RNA extraction was purchased from Life Technologies
(Grand Island, NY). Polyvinylidene difluoride (PVDF) membranes,
protein molecular standards, and ECL plus chemiluminescent system for
Western immunoblots were from Amersham (Arlington Heights, IL),
rabbit polyclonal antibodies against Bcl-x, Bax, Bad, Poly(ADP-ribose)
polymerase (PARP), and caspase-3 were from Santa Cruz Biotechnology
(Santa Cruz, CA), and Bcl-2 was from Upstate Biotechnology (Lake
Placid, NY).
Tg mice. Generation of IGF-II /IGF-I Tg mice has been described in
detail elsewhere (Ye et al., 1996). They were bred as heterozygotes and
maintained in a vivarium with 12 hr (light /dark) cycles at 22°C. All
procedures used were approved by appropriate committees at the Uni-
versity of North Carolina at Chapel Hill.
Brains from IGF-II /IGF-I Tg mice and their normal, non-Tg litter-
mates were collected at P7, P14, and P21 (n $ 5 for most experiments).
Tg mice were identified by Northern hybridization analysis of total RNA
prepared from the cerebral cortex (the transgene is expressed in all brain
regions at all postnatal ages), as previously described (Chrysis and
Underwood, 1999). Briefly, 20 mg of total RNA were electrophoresed in
1.2% formaldehyde–agarose gel, transferred to positively charged mem-
branes, and UV cross-linked. Membranes were hybridized with
digoxenin-labeled RNA probes transcribed from the human IGF-I cDNA
used in transgene, washed at high stringency, and detected by chemilu-
minescence. Transgene transcripts were observed in multiple sizes of
;2.8, 1.2, and 0.9 kb, as described previously (Ye et al., 1996) and were
much more abundant than endogenous IGF-I mRNA.
Detection of apoptosis. Apoptotic cells in CB of Tg mice and their
normal littermates were identified by terminal deoxynucleotidyl
transferase-mediated deoxy-UTP nick end labeling (TUNEL), according
to the manufacturer’s instructions (Oncor, Gaithersburg, MD). Briefly,
mice were perfused with 4% paraformaldehyde in 0.1 M PBS. The
brainstem was transected in the transverse plane just rostral to the pons,
and both the brainstem and CB were removed as a single piece. After
paraffin embedding, serial sections were cut at a thickness of 5 mm, and
every sixth section in the series was mounted on glass slides. Deparaf-
finized and rehydrated sections were treated with proteinase K (15
mg/ml) at 37°C for 10 min, and endogenous peroxidase activity was
blocked with 3% hydrogen peroxide. Slides were then placed in equili-
brating buffer and incubated in a reaction buffer containing TdT and
dUTP for 60 min at 37°C. After rinsing, slides were incubated with
peroxidase-conjugated anti-digoxigenin (introduced together with Triton
X-100 and a blocking agent). The sections were then exposed to 0.5
mg/ml diaminobenzidine and 0.05% hydrogen peroxide to generate a
brown reaction product and covered with Crystal /Mount (Biomeda,
Foster City, CA). At least six sections, 25 mg apart (to avoid counting the
same cells twice) were used to determine the number of apoptotic cells.
For each section, cerebellar two-dimensional maps were traced using a
camera lucida. Completed maps were then digitized and measured using
the Image-Pro image analysis system (Media Cybernetics, Silver Spring,
MD). The number of apoptotic cells in each cerebellar section was
counted. Apoptotic cell number was expressed as a function of cell
density (cells per square millimeter).
RPA. Probe template cDNAs for mouse cyclophilin, Bcl-x, Bax, and
Bcl-2 were purchased from Ambion. The Bcl-x riboprobe can protect
fragments of 60–80 nucleotide (nt) and 215 nt corresponding to Bcl-x
short (Bcl-xS) and long (Bcl-xL), respectively. The Bax protects a 167 nt
fragment, Bcl-2 protects a 191 nt fragment, and the cyclophilin protects
a 103 nt fragment. A mouse Bad cDNA of 419 bp was prepared by reverse
transcription of mouse brain RNA, followed by amplification by PCR
using primers designed according to the published sequence (Yang et al.,
1995). The antisense primer was 59-CTAAGCTCCTCCTCCATCCC-39
(nucleotides 834–853), and the sense primer was 59-AGGACTTATCA-
GCCGAAGCA-39 (nucleotides 434–453). The T3 promoter consensus
sequence was linked to the 59-end of the antisense primer, and the T7
promoter consensus sequence was linked to the 59-end of the sense
primer. PCR yielded one fragment at expected size that was then
amplified and purified. Purified product was digested with the appropri-
ate restriction enzymes to confirm its identity. Riboprobes were prepared
by in vitro transcription and purified on 5% acrylamide/8 M urea gel.
RPA was performed as reported previously (Chrysis et al., 1998).
Briefly, 20 mg samples of CB total RNA were hybridized overnight at
45°C with biotin-labeled riboprobes (3 fmol of cyclophilin, 2.5 fmol of
Bcl-x and Bax, or 3 fmol of cyclophilin, 3 fmol of Bad, and 2 fmol of
Bcl-2). After hybridization, samples were treated with A and T1 RNases,
and protected fragments were separated in 8% acrylamide/8 M urea gels
and transferred to positively charged membranes by electroblotting.
After washing, the signal was detected according to manufacturer’s
recommendations (Ambion). Pilot experiments using constant amount of
probes but different concentrations of RNA confirmed that the concen-
tration of probes was in molar excess. Yeast RNA hybridized with the
above probes confirmed that the digestion was complete. Bcl-x and Bax
were studied in the same reaction because their protected bands can be
easily distinguished on the basis of size, and their abundances are
similar. Protected bands for Bcl-2 and Bad were much less abundant,
requiring longer exposure times to develop their signals, and thus, they
were studied together in the same reaction. The signal for each protected
band was normalized to that of cyclophilin and expressed as the ratio to
the cyclophilin signal.
Western immunoblot. Total protein extracted from the CB with the
modified RIPA buffer (Tris–HCl 50 mM, pH 7.4, NP-40 1%, Na-
deoxycholate 0.25%, NaCl 150 mM, EDTA 1 mM, PMSF 1 mM, aproto-
nin, leupeptin, and pepsatin, 1 mg/ml each, Na3VO4 1 mM, NaF 1 mM)
was measured according to the Bradford method (Bio-Rad, Hercules,
CA). Equal amounts of proteins (30 mg for Bcl-x, Bax, Bad, and PARP;
40 mg for caspase-3 at P7 and 60 mg at P14 and P21; and 120 mg for Bcl-2
detection) were fractionated by 12% (or 8% for PARP) SDS-PAGE
under reducing conditions. Resolved proteins were electrophoretically
transferred to PVDF membranes, blocked overnight at 4°C in NAP-Sure
(Geno Technology, St. Louis, MO) diluted 1:1 in Tris-buffered saline
(TBS; 10 mM Tris and 150 mM NaCl, pH 7.5). They were then incubated
with primary antibodies (antibodies against Bcl-x, Bad, Bax, PARP, and
caspase-3 at 1:2000, and antibody against Bcl-2 at 1:3500) in a 1:3 dilution
of NAP-Sure/TBS at room temperature for 1 hr, washed in TBS with
0.1% Tween 20 several times, and incubated with horseradish
peroxidase-conjugated anti-rabbit Ig (Transduction Laboratories, San
Diego, CA) at 1:10,000 dilution. The antigen–antibody complexes were
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then detected by chemiluminescence. After development of films, blots
were stained with Coomassie blue to assure equal loading of total
protein. All experiments were repeated at least twice using two different
group of mice.
Statistics. Data were calculated as means and SDs, and results were
analyzed by Student’s t test. p values ,0.05 were considered statistically
significant.
RESULTS
Apoptosis during postnatal cerebellar development
To assess whether IGF-I overexpression alters apoptosis during
cerebellar development, we used the TUNEL method to identify
apoptotic cells at P7, P14, and P21. At P7 IGF-I Tg mice had
significantly fewer apoptotic cells compared with their normal
littermates (Fig. 1; 35.4 6 11.3 cells/mm2 in Tg mice and 66.7 6
6.7 in littermate controls; p , 0.01). At P14, Tg mice also exhib-
ited a decrease in apoptotic cell number (16.0 6 1.9 cells/mm2 in
Tg mice, compared with 37.5 6 16.6 cells/mm2 in controls), but
the statistical significance was marginal ( p 5 0.09) because of the
variability in normal littermates. Apoptotic cells were located
mostly in the external granule layer (EGL). There were fewer
apoptotic cells in the internal granule layer (IGL). Compared
with P7 and P14, the number of apoptotic cells at P21 was
markedly decreased in both Tg and controls. Nonetheless, Tg
animal tended to have fewer apoptotic cells (0.57 6 0.2 cells/mm2
in Tg mice, compared with 1.24 6 0.5 cells/mm2 in controls, p 5
0.14). At this time, most apoptotic cells were located in the
internal granule layer.
Caspases
Because caspases are thought to be the ultimate effectors of
apoptosis in many situations, we investigated the abundance of
caspase-3 to determine whether IGF-I modulates its expression in
the CB during early postnatal development. Western immuno-
blots for caspase-3 revealed that pro-caspase-3 was decreased in
CBs from Tg mice at all ages studied, compared with normal
littermates (Fig. 2 shows data from Tg mice expressed as a
percentage of that in normal, control mice). This finding was
consistent in several experiments from different groups of mice.
The decrease in pro-caspase-3 in Tg mice does not reflect in-
creased consumption of pro-caspase-3, however, because Tg mice
also exhibited comparable decreases in caspase-3, the 20 kDa
procaspase-3 cleavage product. More specifically, at P7 pro-
caspase-3 was decreased by 59% in Tg mice (302 6 42 arbitrary
units in Tg mice, compared with 512 6 74 in controls; mean 6
SD; p , 0.05), whereas the 20 kDa fragment was decreased by
77% (120 6 30, compared with 533 6 111 in controls; p , 0.01);
at P14 pro-caspase-3 was decreased 63.5% in Tg mice (343 6 65,
compared with 940 6 137 in controls; p , 0.01), and the cleavage
product was decreased by 68% (225 6 53, compared with 571 6
97 in controls; p , 0.05); and at P21 these respective decreases
were 60% (113 6 46, compared with 286 6 35; p , 0.05) and 52%
(32 6 6, compared with 67 6 13; p , 0.05) (Fig. 2). During early
postnatal cerebellar development, therefore, IGF-I overexpres-
sion appears to decrease the expression of pro-caspase-3 without
an apparent alteration in its activation, as judged by the relative
abundance of its cleavage product.
PARP
PARP, a 116 kDa protein, is a substrate for caspases and cleaved
during apoptosis to an 85 kDa fragment. To obtain a measure of
caspase activity, therefore, we assessed the abundance of PARP
and its caspase-cleaved product. The abundance of 116 kDa
PARP decreased during normal cerebellar development (Fig.
3A). The relative abundance of the 85 kDa fragment, however,
was not concordant with that of 116 kDa PARP, because its
abundance was lower at P14 than at P7 and P21. The latter finding
suggests that PARP is less actively cleaved at this time. The
abundance of 116 kDa and 85-kDA PARP in Tg mouse CBs
changes in a similar manner (Fig. 3B).
Compared with normal controls, P7 Tg mice exhibited a 76%
decrease in 85 kDa PARP fragment ( p , 0.05) without a signif-
icant change in the abundance of the uncleaved protein (Fig. 4A
shows representative Western blots, and B depicts the abun-
dances of 85 and 116 kDa PARP in Tg mice expressed as a
percentage of that in control mice). The ratio of 85 kDa to 116
kDa PARP in P7 Tg mice, therefore, was 25% (0.112 6 0.015) of
Figure 1. Representative microphotographs from TUNEL assay in CBs
from control (C) and IGF-I overexpressing transgenic (Tg) mouse at P7.
CBs from P7 Tg animals had a 47% decrease in the number of apoptotic
cells.
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the ratio in controls (0.45 6 0.03; p , 0.0001). This lower ratio in
Tg mice is likely to reflect decreased 116 kDa cleavage, and in
turn decreased caspase activity. At P14 both the 85 kDa cleaved
fragment and intact PARP were significantly reduced in Tg mice
(by 73 and 69%, respectively; p , 0.01), but the 85 to 116 kDa
PARP ratio was not significantly reduced (87% of control; 0.13 6
0.016 in Tg mice and 0.15 6 0.02 in controls). At P21, both 85 kDa
and 116 kDa PARP remained decreased (73 and 45% decreases,
respectively), but the differences in the 116 kDa PARP did not
meet tests of statistical significance. The ratio of 85 to 116 kDa
PARP, however, was reduced by 50% in Tg mice (5 6 0.6),
compared with controls (10 6 1.6; p , 0.0001). These findings
suggest that IGF-I overexpression reduces PARP expression in
the CB during development. In addition, it seems likely that the
decrease in the abundance of p85 kDa PARP relative to that of
116 kDa PARP at P7 and P21 reflects reduced caspase activity.
IGF-I overexpression modulates the Bcl family of
gene expression
The Bcl family of proteins, named for the prototype Bcl-2 gene,
are intimately involved in the regulation of apoptosis. Bcl pro-
teins, such as Bcl-2 and Bcl-xL, exert anti-apoptotic effects,
whereas others have proapoptotic actions, e.g., Bax, Bad and
Bcl-xS. To determine whether IGF-I altered their expression in a
manner consistent with IGF-I anti-apoptotic actions, we deter-
mined the mRNA and protein abundance of Bcl family members
with different apparent actions on apoptosis. At each age studied
during cerebellar development, the expression of Bcl-2 and Bad
(both mRNA and protein) was markedly less than that of Bcl-x
and Bax. These differences in abundance necessitated using dif-
ferent experimental conditions (e.g., differing exposure times for
RPAs and differing amounts of proteins for western immuno-
blots) for each measure, and thus, only direct comparisons be-
tween Tg and normal CBs could be made, i.e., quantitative
comparisons among Bcl proteins during development were not
possible.
We obtained data on the expression of two anti-apoptotic Bcl
family members, Bcl-2 and Bcl-xL. Although the Bcl-x riboprobe
used could detect both Bcl-xL (a 215 nt band) and Bcl-xS (60–80
Figure 2. Pro-caspase 3 (32 kDa) and its cleaved fragment caspase-3 (20
kDa) in Tg mice and their normal littermates during cerebellar develop-
ment. A shows representative Western immunoblots from Tg mice and
their normal littermates (controls) at P7, P14, and P21. B, Chemilumines-
cent signals were scanned for pro-caspase 3 (black bars) and its 20 kDa
cleaved fragment (hatched bars) from P7, P14, and P21 Tg and control
mice. For each developmental age studied, arbitrary optical density units
for Tg mice are expressed as a percentage of control. Values represent the
mean 6 SD; *p , 0.05; **p , 0.01. Figure 3. Changes in PARP abundance in Tg and normal mice during
CB development, as assessed by Western immunoblot. A, Developmental
changes of PARP (black bars) and its 85 kDa cleaved fragment (white bars)
in CBs from control mice. Values represent the mean 6 SD of arbitrary
units derived from chemiluminescent signals. B, Developmental changes
of PARP (black bars) and its 85 kDa cleaved fragment (white bars) in CBs
from Tg mice. Values represent the mean 6 SD of arbitrary units derived
from chemiluminescent signals. *p , 0.05; **p , 0.01; ***p , 0.001.
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nt), no signals for the Bcl-xS transcript were detected in either Tg
or normal mice at any age studied. Consistent with this finding,
only the 29 kDa Bcl-xL protein was detected by Western analysis.
Compared with their normal littermates at P7 (Fig. 5), Bcl-xL
mRNA abundance was increased by 92% in Tg mice (0.27 6
0.006 arbitrary units, compared with 0.14 6 0.01 in controls;
mean 6 SD; p , 0.001) and that of Bcl-xL protein by 134%
(2088 6 314 arbitrary units, compared with 892 6 183; p 5 0.01;
Fig. 6), whereas at P14 and P21 both mRNA and protein for
Bcl-xL were similar in Tg and their normal littermates (at P14:
0.25 6 0.01 in Tg mice, compared 0.26 6 0.01 in controls, p 5
NS, and 1749 6 115 in Tg mice, compared with 1792 6 308 in
controls, p 5 NS, respectively; and at P21: 0.405 6 0.03 in Tg
mice, compared with 0.451 6 0.017, p 5 NS; and 1670 6 78 in
Tg mice, compared with 1931 6 123 in controls, p 5 NS,
respectively).
At P7 Bcl-2 mRNA abundance in Tg mice also was increased
(72%; 0.1798 6 0.013 arbitrary units, compared with 0.1043 6
0.001; p , 0.01), but at P14 and P21 its abundance did not differ
from that of control mice (0.168 6 0.01 in Tg mice, compared
with 0.148 6 0.005 in controls, and 0.209 6 0.010 in Tg mice,
compared with 0.206 6 0.01, respectively; p 5 NS; Fig. 5). The
abundance of Bcl-2 protein was very low in Tg and control CBs,
and thus, quantification was not possible. At P7, however, Bcl-2
abundance appeared to be increased in Tg mice. At P14 and P21
Bcl-2 protein was even less abundant, and no differences could be
discerned between Tg and normal CBs.
Changes in the expression of proapoptotic Bcl family members
also were observed in Tg mice. At P7 Bax mRNA was increased
by 67% (0.066 6 0.006 arbitrary units in Tg mice, compared with
0.04 6 0.004 in controls; p , 0.01; Fig. 5), but Bax protein was
unchanged (524 6 68 in Tg mice, compared with 568 6 103 in
controls; p 5 NS; Fig. 6). At P14 Bax mRNA was unchanged
(0.112 6 0.01 in Tg mice, compared with 0.132 6 0.005; p 5 NS),
but protein abundance was decreased by 35% in Tg mice (776 6
125 in Tg mice, compared with 1187 6 126; p , 0.05), whereas at
P21 both Bax mRNA (0.185 6 0.004 in Tg mice, compared with
0.245 6 0.012; p , 0.01) and protein abundance (913 6 152 in Tg
mice, compared with 3816 6 646; p , 0.01) were decreased in Tg
mice (by 25 and 75%, respectively), compared with normal
littermates.
Bad mRNA was increased by 43% in P7 Tg mice (0.600 6 0.08
arbitrary units in Tg mice, compared with 0.391 6 0.03; p , 0.05).
Bad protein abundance was similar in Tg and normal mice (996 6
289 in Tg mice, compared with 902 6 172; p 5 NS), but marked
variations in protein abundance were observed, especially in Tg
mice. In five different experiments from three different groups of
mice, Bad protein was found to be either unchanged or moder-
ately increased (by up to 35%) in Tg mice, but because of the high
variability in Tg mice, these findings were not significant. Bad
Figure 4. PARP protein from CBs of Tg and normal littermates, assessed
by Western immunoblot. A shows representative Western immunoblots of
116 kDa PARP and its 85 kDa cleavage fragment in CBs from normal
controls (C), and Tg mice at P7, P14, and P21. B, The abundance (mean 6
SD) of PARP and its 85 kDa fragment in Tg CBs expressed as a
percentage of that in their normal littermates. *p , 0.05; **p , 0.01.
Figure 5. Effects of IGF-I overexpression on Bcl-xL Bcl-2, Bax, and Bad
mRNAs assessed by RPA. A, Biotin-labeled gel-purified Bcl-x, Bax, and
mouse cyclophilin riboprobes were cohybridized with 20 mg of total RNA
from CBs. Each of the protested bands was of the expected size, i.e., 201,
167, and 100 nt, respectively. Bad, Bcl-2, and cyclophilin riboprobes also
were cohybridized with 20 mg of total RNA giving bands of the expected
sizes (491, 191, and 100 nt, respectively). B, Autoradiographic signals were
scanned, normalized to those from cyclophilin, and expressed as a ratio of
the signal to that of cyclophilin. Data (mean 6 SD) from Tg mice is
expressed as a percentage of their normal littermates. Hatched bars
represent Bcl-2, white bars Bcl-x, black bars Bax, and cross-hatched bars
Bad. *p , 0.05; **p , 0.01; ***p , 0.001.
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immunostaining at P7 revealed doublet bands. It is likely that one
of these bands represents phosphorylated Bad. The resolution of
the doublets on our gels did not permit quantification of each
separately. We, however, had the impression that the abundance
of the lower band was more variable and may have accounted for
the variability of Bad abundance, especially in Tg CBs. At P14
Bad mRNA abundance was decreased by 36% in Tg mice (0.48 6
0.06 in Tg mice, compared with 0.68 6 0.03; p , 0.05), and
protein abundance was decreased by 47% (441 6 80 in Tg mice,
compared with 803 6 176; p 5 0.036). At P21 Bad mRNA was
decreased by 50% (0.093 6 0.0020 in Tg mice, compared with
0.186 6 0.017; p , 0.001) and protein by 62% (231 6 45 in Tg
mice, compared with 604 6 74; p , 0.01). Doublet Bad immu-
nostaining was not obvious at P14 and not observed at P21.
Our results demonstrate that IGF-I overexpression in the post-
natal CB alters Bcl family gene expression in a developmentally
specific manner. At P7 the abundance of each Bcl mRNA was
significantly increased, but only Bcl-xL protein abundance was
increased, whereas at P14 and P21, Bax and Bad expression were
decreased. Each of these changes is consistent with IGF-I anti-
apoptotic actions, and changes in protein abundance are concor-
dant with the inhibition of apoptosis.
DISCUSSION
We report that postnatal cerebellar IGF-I overexpression atten-
uates the apoptosis occurring in granule cells during cerebellar
development. Greater than 85% of the apoptotic cells identified
were in granule cell layers, and IGF-I inhibition of apoptosis was
similar in both the EGL and IGL. We believe that IGF-I derived
from Purkinje cells exerts anti-apoptotic actions directly on gran-
ule cells, because the transgene (Ye et al., 1996), like the native
gene (Bondy and Lee, 1993), is expressed by Purkinje cells and
because IGF-I has been shown to inhibit apoptosis in primary
cultures of granule cells (D’Mello et al., 1993; Leski et al., 2000).
Our data, however, do not exclude indirect IGF-I effects on
granule cells. IGF-I-induced decreases in apoptosis are associ-
ated with alterations in the expression of the Bcl family of
proteins. Furthermore, altered Bcl expression occurs in a devel-
opmentally specific manner, such that in early postnatal life (P7)
there is increased expression of the anti-apoptotic genes, Bcl-xL
and Bcl-2, whereas at later ages (P14 and P21) the expression of
proapoptotic proteins, Bax and Bad, is decreased. These changes
are associated with decreases in the expression of procaspase-3
and the active enzyme, caspase-3, and decreased caspase-3 activ-
ity, as judged by decreased abundance of the 85 kDa PARP
cleavage product.
Between P5 and P9 of rodent cerebellar development, granule
cells undergo a major wave of classical apoptosis, i.e., pro-
grammed cell death characterized by DNA fragmentation, (Lan-
dis and Sidman, 1978; Wood et al., 1993). As judged by TUNEL,
we found that postnatal cerebellar IGF-I overexpression attenu-
ates apoptosis significantly during this time (P7). Inhibition of
premitotic granule cells apoptosis at P7 could result in a large
increase in granule cell number, especially if all or most such cells
subsequently undergo one or more rounds of division. Given that
granule cell apoptosis was decreased in throughout both the EGL
and IGL of Tg mice, IGF-I likely inhibits apoptosis of both
premitotic and in postmitotic cells. Our study, however, was not
designed to address this question.
Although not meeting tests of statistical significance, CBs from
Tg mice had ;50% fewer apoptotic cells at P14 and P21. A
number of other lines of evidence, however, strongly suggest that
IGF-I overexpression inhibits apoptosis at ages beyond the first
week of postnatal development: (1) cerebellar overgrowth in
IGF-I Tg mice continues until adulthood, despite the fact that our
previous studies only detected evidence of small increases in
granule cell proliferation (;10%) at one time during postnatal
development (P15) (Ye et al., 1996); (2) the abundance of the 85
kDa fragment of PARP, which can result from caspase cleavage
during apoptosis, is significantly reduced in CBs from Tg mice at
P21; (3) both procaspase 3 and its active fragment are significantly
decreased at P21, suggesting decreased apoptotic activity; and (4)
the abundance of the proapoptotic proteins Bax and Bad are
significantly decreased in CBs from Tg mice at P14 and P21. More
detailed morphometric studies will be necessary to determine the
times when IGF-I anti-apoptotic actions have their greatest im-
pact on granule cell number.
PARP synthesizes poly-ADP-ribose from nicotine amid dinu-
cleotide in response to DNA strand breaks and is involved in
many genomic processes, including DNA base excision repair
(Satoh et al., 1994) and DNA replication (Yoshida and Simbulan,
1994). PARP was one of the first substrates shown to be cleaved
by caspases. Although its role in apoptosis is not clear, a reduc-
tion in PARP cleavage can be taken as evidence of decreased
Figure 6. Effects of IGF-I overexpression on the Bcl-xL , Bax, and Bad
proteins assessed by Western immunoblot in CBs from P7, P14, and P21
Tg mice and their normal littermates. A shows representative Western
immunoblots of Bcl-x, Bax, and Bad in CBs from Tg and normal (C) mice
at P7, P14, and P21. B, Data (mean 6 SD) from Tg mice is expressed as
a percentage of their normal littermates. White bars represent Bcl-x,
hatched bars Bax, and black bars Bad.
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apoptosis resulting from decreased caspase activity. Our findings
of decreases in the abundance of procaspase-3 and its activated
enzyme at each age studied are consistent with the latter specu-
lation. A reduction in caspase activity, thus, could account for the
decrease in cleaved PARP and represent a downstream mecha-
nism for IGF-I anti-apoptotic actions. Relative to littermate con-
trols, we found a decrease in cleaved PARP in the CBs of Tg mice
at each time studied, as well as decreased PARP expression at
P14. We also observed that PARP abundance decreased in nor-
mal mice during this period of cerebellar development. The
progressive decrease in PARP expression, therefore, also might
be a reflection of the normal diminution in cell proliferation, and
consequently decreased requirement for DNA repair, which oc-
curs during the same period.
At P7 before the expression of the IGF-I transgene has reached
its peak [peak abundance occurs by ;P20 (Ye et al., 1996)],
mRNA and protein abundances for the anti-apoptotic Bcl-2 and
Bcl-xL are increased. The anti-apoptotic actions of Bcl-2 and
Bcl-xL are well established in cultured neurons (Batistatou et al.,
1993; Allsopp et al., 1993, 1995; de Luca et al., 1996) and in vivo
models (Martinou et al., 1994; Farlie et al., 1995; Gonzalez-
Garcia et al., 1995; Motoyama et al., 1995; Michaelidis et al., 1996;
Zanjani et al., 1996, 1997). We speculate, therefore, that the
increase of Bcl-2 and Bcl-xL in CBs from Tg mice contributes to
the decreased apoptosis found in these mice at P7. The induction
of Bcl-2 and Bcl-xL mRNAs and their proteins by IGF-I overex-
pression is consistent with in vitro studies showing that IGF-I
induces Bcl-2 promoter activation (Pugazhenthi et al., 1999) and
expression of the Bcl-xL gene product in PC12 cells (Parrizas and
LeRoith, 1997). The upregulation of Bcl-2 and Bcl-xL expression,
however, appeared to be specific to the stage of development,
because we observed no difference between Tg and normal mice
at P14 or P21. Although we have no explanation for the latter, it
seems possible that the failure of IGF-I to increase Bcl-2 and
Bcl-xL expression at later ages could reflect a compensatory
mechanism. This speculation is consistent with the finding that
IGF-I-induced Bcl-xL expression in cultured PC12 cells exhibits
peaks 3 and 24 hr after IGF-I exposure, but then declines (Par-
rizas and LeRoith, 1997).
Transcription of the Bcl-x gene generates two alternatively
spliced mRNAs: a long form, termed BCL-xL, which encodes a
protein with anti-apoptotic activity, and a shorter form, Bcl-xS,
which encodes a proapoptotic protein (Boise et al., 1993). The
riboprobe used for RPAs and the antibody used in Western
immunoblots each recognize both forms of Bcl-x. We, however,
did not detect Bcl-xS in any experiment. This result is consistent
with a report that mouse tissues, including brain, do not express
Bcl-xS mRNA as judged by both S1 nuclease protection assay and
PCR (Gonzalez-Garcia et al., 1994).
The expression of the proapoptotic genes Bax and Bad also
were affected by IGF-I, but in a manner different from Bcl-2 and
Bcl-xL. At P7 IGF-I increased the mRNA abundance of both, but
their protein abundance was not altered at this time, whereas at
P14 and P21 IGF-I decreased the expressions of each in a manner
that appeared to be progressive with time. Furthermore, the
relative decrease in protein abundance appeared greater than the
decrease in mRNA abundance, suggesting the possibility of de-
creased mRNA translation or increased protein degradation. The
increase of Bax and Bad mRNAs at P7 in Tg mice seems para-
doxical in the view of the IGF-I anti-apoptotic role. We speculate
that this may represent an adaptation to the increase in Bcl-2 and
Bcl-xL expression, rather than a direct effect of IGF-I overexpres-
sion. As mentioned above, expression of the IGF-I transgene
peaks at ;P20, the time when we observed a nadir in Bax and
Bad expression. This pattern leads us to speculate that higher
IGF-I levels are necessary for IGF-I to modulate the expression
of these proapoptotic proteins. Nonetheless, IGF-I actions on Bax
and Bad expression may be crucial to its anti-apoptotic actions.
Bax is clearly important in regulating apoptosis in the CNS
(Gillardon et al., 1995; Krajewski et al., 1995; Miller et al.,
1997; Shindler et al., 1997; Vekrellis et al., 1997; Doughty et
al., 2000; Selimi et al., 2000) and especially in cerebellar
granule cells (Krajewski et al., 1995; Miller et al., 1997;
Doughty et al., 2000; Selimi et al., 2000). For example, apo-
ptosis after cerebral ischemia is associated with increased Bax
expression in the CB (Doughty et al., 2000). Furthermore,
cerebellar granule cells from Bax-deficient mice are resistant
to apoptosis (Miller et al., 1997), and Bax deficiency in
Lurcher mice rescues granule cells from apoptosis (Doughty et
al., 2000; Selimi et al., 2000).
Bad promotes cell death by binding to and blocking the anti-
apoptotic activity of Bcl-xL (Yang et al., 1995). When Bad is
phosphorylated, it dissociates from Bcl-xL, freeing Bcl-xL to exert
its activity as a suppressor of apoptosis. Phosphorylation of Bad
takes place after activation of the PI3-K and its downstream
target, the serine–threonine kinase Akt (Datta et al., 1997; del
Peso et al., 1997). IGF-I-induced neuronal survival has been
linked to the activation of the PI3-K pathway and the subsequent
inactivation of Bad resulting from Akt phosphorylation (Datta et
al., 1997). The antibody we used to detect Bad recognizes both
phosphorylated and nonphosphorylated forms, and it is likely that
one of the doublet bands noted on P7 Western blots represents
phosphorylated Bad. The more slowly migrating band in the
doublet was abundant in P7 CBs, but was not detected at P14 or
P21. We suspect that this band represents phosphorylated Bad
and that the high variability noted in Bad protein levels at P7 in
Tg mice are related to dynamic changes in Bad isoforms induced
by phosphorylation at this developmental time. A high proportion
of phosphorylated Bad would also contribute to the significant
reduction in apoptosis that occurs in P7 Tg mice. An antibody
specific for phosphorylated Bad would provide more definitive
information.
Whereas IGF-I anti-apoptotic effects have been well docu-
mented in cultured cells, in vivo studies are few. A number of
studies indicate that intraventricular IGF-I administration can
protect against neuron injury after hypoxia–ischemia (Guan et
al., 1996, 2000; Johnston et al., 1996), and Wang et al. (2000)
demonstrated that topical IGF-I application on the cerebral cor-
tex can ameliorate apoptosis after ischemia. Recent evidence
indicates that systemically administered IGF-I can cross the
blood–brain barrier (Armstrong et al., 2000). Furthermore, sys-
temically administered IGF-I appears capable of protecting neu-
ron from injury-induced apoptosis (Tagami et al., 1997). There-
fore, IGF-I appears capable of protecting against injury-induced
neuron death.
In summary, our data demonstrate that IGF-I attenuates apo-
ptosis during cerebellar development by affecting multiple steps
in the apoptotic pathway in a developmentally specific manner.
We believe that our data indicates an important role for IGF-I in
the normal control of apoptosis during CB development and that
it could be useful in the therapy of a variety of neural injuries and
disorders.
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